Treatment of early favorable and early unfavorable hodgkin lymphoma – combined modality therapy?

Hodgkin lymphoma has become one of the most curable malignancies today. This is particularly true for patients with early stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small field radiotherapy. More recent clinical trials such as the GHSG HD10 study demonstrated, that even two cycles of ABVD followed by 20Gy IF-RT are sufficient and result in more than 90% of patients being cured. The current treatment for early unfavorable patients is either four cycles of ABVD plus 30Gy IF-RT or two cycles of BEACOPPescalated followed by two cycles of ABVD plus IF-RT.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research